Navigation Links
BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market
Date:8/20/2014

BURLINGTON, Mass., Aug. 20, 2014 /PRNewswire/ -- Decision Resources Group finds that the vascular access device market in Brazil, Russia, India and China (BRIC) was valued at approximately $1.6 billion in 2013, roughly equal to the size of the United States market that year. Going forward, however, the BRIC market will experience much faster growth as a result of strong economic expansion, improving access to healthcare and the aging population.

Other key findings from Decision Resources Group's coverage of the BRIC vascular access device market:

  • Short PIVCs: There will be a continuous shift away from the use of steel needles for intravenous infusions to short peripheral intravenous catheters (PIVCs), which boast a much lower risk of phlebitis and extravasation. This shift will be particularly notable in China, where the government recently decided to no longer reimburse steel needles.
  • PICCs: In regions where central venous catheter (CVC) use is currently common, there will be a shift toward peripherally inserted central catheters (PICCs), which offer a lower risk of infection. A major driver of PICC adoption is the fact that they can be placed by nurses, thereby reducing procedural costs.
  • Implantable ports: Implantable ports are the most expensive of the vascular access devices, but offer convenience for patients who will require long-term vascular access, such as those undergoing chemotherapy. Although the premium price of these products continues to restrict their use in the BRIC countries, adoption will still grow through 2022, particularly in China and Russia.

Comments from Decision Resources Group Analyst Jonathan Sawatsky:

  • "Adoption of premium-priced safety, tunneled, antimicrobial and power-injectable devices will help to support overall pricing in the BRIC vascular access device market. In particular, physicians are realizing the need for safety short PIVCs, which reduce needlestick injuries. Although Brazil was the only BRIC country in 2013 with legislation mandating the use of these products, their usage will increase in each of the countries through 2022."
  • "Low-cost domestic competitors continue to be successful in the BRIC countries despite the fact that their products are generally perceived to be of lower quality. However, competition from these companies is less significant in markets where quality is considered more important, such as in the case of PICCs, tunneled CVCs and implantable ports."

Additional Resources:

  • Jonathan Sawatsky has written a Medtech 360 report on this subject entitled BRIC Markets for Vascular Access Devices 2014. A separate report entitled Chinese Markets for Vascular Access Devices 2014 will be available later this year and will include market valuations broken down at the regional level.

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresourcesgroup.com

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO


'/>"/>

SOURCE Decision Resources Group
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Bayer HealthCares Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon
2. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
3. MiMedx Group, Inc. to Present at the 6th Annual Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders Conference
4. Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease
5. BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease
6. FirstMark to Exhibit at Cardiovascular Research Technologies (CRT) 2012 Conference
7. Biotech Firm Spun Off from Childrens Hospital Raises $7 Million to Advance Magnetic-Based Vascular Treatment
8. SPX-106T Arrests Development of Atherosclerotic Plaques in Mouse Model of Cardiovascular Disease
9. Foundation for Health Improvement and Technology (FHIT) Launched to Beat Cardiovascular Disease
10. HemoShear to Present at Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) Conference
11. International Survey of T2* Cardiovascular Magnetic Resonance in Thalassemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2019)... ... September 10, 2019 , ... An upcoming ... the latest developments in genome sequencing analysis. Check your local listings for more ... at Rivermap Research & Consulting and will explore its revolutionary pathogenic DNA analysis ...
(Date:9/8/2019)... ... September 05, 2019 , ... Spartan Bioscience, the ... of Finance for Shopify, has been named Chief Financial Officer. , Spartan ... Finlayson as strategic advisors. Additionally, Spartan has hired Steve Edgett as Executive Vice ...
(Date:8/29/2019)... ... August 28, 2019 , ... DuPont Nutrition ... solutions to attendees at the International Baking Industry Expo, September 8 to 11, ... optimizing production efficiency to cost and waste reduction and from maintaining freshness throughout ...
(Date:8/25/2019)... ... 23, 2019 , ... Authors Gopal Nayak and Mahendra Kumar ... book “Impact of Biofield Treatment on Growth and Anatomical Characteristics of Pogostemon cablin ... The book garnered No. 1 status on Amazon in several categories including: Mind-Body ...
Breaking Biology Technology:
(Date:8/31/2019)... ... 30, 2019 , ... Today marks the introduction of Natalist, ... the preconception period with doctor-approved products and resources, including The Get Pregnant Bundle, ... to get pregnant. , Natalist is built on the values of evidence, education, ...
(Date:8/29/2019)... ... August 28, 2019 , ... Salimetrics, ... passed their five-year milestone of collaboration in salivary bioscience stress research. ... primary focus towards performing feasibility studies, phase 1 – phase 4 clinical ...
(Date:8/27/2019)... ALISO VIEJO, Calif. (PRWEB) , ... August 27, ... ... clinical genetics testing company, announced today new opportunities to improve genetic testing guidelines. ... on how to improve the guidelines to identify more at-risk patients. , ...
Breaking Biology News(10 mins):